Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Hypertension

Eligibility:

All Genders

20-80 years

Brief Summary

PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk f...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Male or female
  • Aged 20 to 80 years old.
  • adult with essential hypertension - either newly diagnosed and untreated, or previously treated and uncontrolled
  • Sitting blood pressure: systolic BP \> 140 mmHg but \< 180 mmHg, and/or diastolic BP \> 90 mmHg but \< 110 mmHg)
  • At least one cardiovascular known risk factor other than hypertension: diabetes/hyperglycaemia, cholesterol /dyslipidemia, a previous cardiovascular event, target organ damage, family history of hypertension or cardiovascular diseases, old age defined as \> 55 years (Males), \> 65 years (Females), smoking, overweight or obese patients or a combination of above risk factors
  • Patients who are assessed to benefit from the intake of angiotensin II receptor blocker (ARB) monotherapy or as add-on medication
  • Exclusion criteria:
  • Patients with contraindications to Telmisartan use (as per the Micardis® Tablets package insert).
  • Known hypersensitivity to the active ingredient or to any of the excipients of Micardis® .
  • Any other clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications.
  • Patients participating in any other clinical trial.
  • Patients already on Micardis® alone or combination
  • Pregnant females, or females breast feeding.

Exclusion

    Key Trial Info

    Start Date :

    May 1 2009

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    Estimated Enrollment :

    3184 Patients enrolled

    Trial Details

    Trial ID

    NCT00936208

    Start Date

    May 1 2009

    Last Update

    April 10 2014

    Active Locations (120)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 30 (120 locations)

    1

    Boehringer Ingelheim Investigational Site 28

    Al Fayyum, Egypt

    2

    Boehringer Ingelheim Investigational Site 18

    Alexandria, Egypt

    3

    Boehringer Ingelheim Investigational Site 19

    Alexandria, Egypt

    4

    Boehringer Ingelheim Investigational Site 20

    Alexandria, Egypt